FALLED 23andme is facing a demand on their plans to sell customer genetic information.
Twenty-seven states and the Columbia district took legal action this week against 23andme in the United States Failure Court of the Eastern Missouri District, the court supervising the bankruptcy procedures in Chapter 11 that the genetic test company entered at the beginning of the year.
States claim that 23andme does not have “the right to sell the genetic identities of its customers to the best officer” unless the company “obtains first[s] Express the informed consent for the transfer/transfer proposed by each affected consumer. “”
They want the Fallas Court to rule on “if and to what extent” the genetic test company can “sell and transfer to a third party of such intimate clients data without first obtaining the informed consent of its customers”, according to the presentation.
In the presentation, the states said that “they were not objectively opposed to any sale”, but “they claim that the express and informed consent of each client is necessary before any transfer of the data of this client can occur”.
The general lawyers who filed the demand represent Arizona, Colorado, Connecticut, the District of Columbia, Florida, Illinois, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Missouri, New Hampshire, New Mexico, New York, North Carolina, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dako, South Dako, South Dako, South Dako, South Dako, South Dako, South Dako, South Dako. Utah, Vermont, Virginia, Washington, Virginia of the West and Wisconsin.
“23andme cannot auction millions of personal genetic information of the people without their consent,” said New York Attorney General Letitia James in a statement.
“Neoyorcan and many others from all over the country trusted 23 Andme with their private information and have the right to know what will be done with their information.”
A spokesman for 23andme told Fox Business that the arguments made by the general lawyers on the demand were “without merit”.
“Sale is allowed under the policies of privacy and the applicable law,” said the spokesman.
“We have required any offering to adopt our policies and comply with the applicable legislation as a condition to participate in our sales process. Customers will continue to have the same rights and protections in the hands of the winning bidder.”
The rest of the bidders, Regeneron Pharmaceuticals and Ttam Research Institute, “have pledged to comply with the 23andme Privacy Policies and will continue to operate 23andme as always operated,” according to the 23andme spokesman.
In May, Regeneron, based in New York, announced that he had been successfully appointed bidder at the auction for “substantially all” of 23andme assets with a $ 256 million offer.
23andme later received a $ 305 million offer from the Anne Wojcicki TTAM Institute of TTam, which set the stage for another auction.
The genetic test company entered Chapter 11 bankrupt in March to facilitate the sale of its business.
In its bankruptcy request, the company had estimated a rank of $ 100 to $ 500 million for its assets, with estimated liabilities in the same rank.
23 and was originally founded in 2006.
#States #legal #shares #23andme #sell #customer #genetic #information #midst #bankruptcy
Image Source : nypost.com